

DAFTAR PUSTAKA

- Ahmad, W., Rehman, I., Majeed, O., Niazi, I. K., Mufti, K. A., & Iqbal, A. (2020). Survival Benefit of Transarterial Chemoembolization for Hepatocellular Carcinoma. *Asia Pacific Journal of Cancer Biology*, 5(2), 43–47. <https://doi.org/10.31557/apjcb.2020.5.2.43-47>
- Akkiz, H., Gieseler, R. K., & Canbay, A. (2024). settingsOrder Article Reprints Open AccessReview Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells. *Int. J. Mol. Sci.*, 25, 7873. <https://doi.org/10.3390/ijms25147873>
- Alwi, I., Setiati, S., Syam, A. F., Sudoyo, A. W., K., M. S., & Nasution, S. A. (2024). *Buku Ajar Ilmu Penyakit Dalam*. PIPInterna Publisher.
- Bansho, E. T. O., Silva, P. E. S., Colombo, B. S., Wildner, L. M., Bazzo, M. L., Dantas-Corrêa, E. B., Schiavon, L. L., & Narciso-Schiavon, J. L. (2018). Prognostic Significance of The New Criteria for Acute Kidney Injury in Cirrhosis. *Annals of Hepatology*, 17(3), 461–469. <https://doi.org/10.5604/01.3001.0011.7390>
- Belcher, J.M., Coca, S.G., Parikh, C.R. (2015). Creatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-Analysis. *PLoS One*, 10(8):e0135625. doi: 10.1371/journal.pone.0135625
- Belcher, J. M. (2023). Hepatorenal Syndrome: Pathophysiology, Diagnosis, and Treatment. *Med Clin North Am*, 107(4), 781–792. <https://doi.org/10.1016/j.mcna.2023.03.009>
- Bera, C., & Wong, F. (2022). Management of hepatorenal syndrome in liver cirrhosis: a recent update. *Therap Adv Gastroenterol*, 15, 17562848221102680. <https://doi.org/10.1177/17562848221102679>
- Bodh, V., Sharma, B., & Sharma, R. (2020). Hepatorenal Syndrome : A Review into Changing Definition, Diagnostic Criteria, Pathophysiology, and Management. *CHRISMED Journal of Health and Research*, 7(2), 83. https://doi.org/10.4103/cjhr.cjhr_117_19
- Brar, G., Greten, T. F., Graubard, B. I., McNeel, T. S., Petrick, J. L., McGlynn, K. A., & Altekruse, S. F. (2020). Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis. *Hepatol Commun*, 4(10), 1541–1551. <https://doi.org/10.1002/hep4.1564>
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 68(6), 394–424. <https://doi.org/10.3322/caac.21492>

- Bressan, A.K., James, M.T., Dixon, E., Bathe, O.F., Sutherland, F.R., Ball, C.G. (2018). Acute kidney injury following resection of hepatocellular carcinoma: prognostic value of the acute kidney injury network criteria. *Can J Surg*, *61*(5):E11-E16. doi: 10.1503/cjs.002518
- Chen, Q.F., Chen, S., Zhao, M.(2025) The Synergistic Mechanisms and Prospects of Transarterial Chemoembolization Combined with Immunotherapy for Hepatocellular Carcinoma. *J Hepatocell Carcinoma*, *12*:841-854. <https://doi.org/10.2147/JHC.S514881>
- Cichos, K.H., Jordan, E., Niknam, K., Chen, AF, Hansen, E.N., McGwin, G. Jr., Ghanem, E.S.(2023). Child-Pugh Class B or C Liver Disease Increases the Risk of Early Mortality in Patients With Hepatitis C Undergoing Elective Total Joint Arthroplasty Regardless of Treatment Status. *Clin Orthop Relat Res*, *1*;481(10):2016-2025. doi: 10.1097/CORR.0000000000002631.
- Choi, S. I., Cho, Y., Ki, M., Kim, B. H., Lee, I. J., Kim, T. H., Kim, S. H., Koh, Y. H., Kim, H. B., Hong, E. K., Kim, C.-M., & Park, J.-W. (2022). Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts. *PLOS ONE*, *17*(3), e0265668. <https://doi.org/10.1371/journal.pone.0265668>
- Crabbs, T. A. (2018). Acute Kidney Injury (AKI)—The Toxicologic Pathologist’s Constant Companion. *Toxicologic Pathology*, *46*(8), 918–919. <https://doi.org/10.1177/0192623318797055>
- Csak, T., & Bernstein, D. (2022). Hepatorenal Syndrome: Pathophysiology. *Clin Liver Dis*, *26*(2), 165–179. <https://doi.org/10.1016/j.cld.2022.01.013>
- Feng, F., & Zhao, Y. (2024). Hepatocellular Carcinoma: Prevention, Diagnosis, and Treatment. *Med Princ Pract*, *33*(5), 414–423. <https://doi.org/10.1159/000539349>
- Fida, S., Khurshid, S.M.S., Mansoor, H. (2020). Frequency of Hepatorenal Syndrome Among Patients With Cirrhosis and Outcome After Treatment. *Cureus*, *12*(8), e10016. <https://doi.org/10.7759/cureus.10016>.
- Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., & Kudo, M. (2020). Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *New England Journal of Medicine*, *382*(20), 1894–1905. <https://doi.org/10.1056/NEJMoa1915745>
- Foglia, B., Turato, C., & Cannito, S. (2023). Hepatocellular Carcinoma: Latest Research in Pathogenesis, Detection and Treatment. *Int J Mol Sci*, *24*(15), 12224. <https://doi.org/10.3390/ijms241512224>
- Forner, A., Reig, M., & Bruix, J. (2018). Hepatocellular Carcinoma. *The Lancet*, *391*(10127), 1301–1314. [https://doi.org/10.1016/S0140-6736\(18\)30010-2](https://doi.org/10.1016/S0140-6736(18)30010-2)

- Gadalean, F., Parv, F., Petrica, L., Sporea, I., Timar, B., Gluhovschi, C., Bob, F., Milas, O., Simulescu, A., Patruica, M., Chisavu, L., Mircea, C., Schiller, A., & Danila, M. (2023). Rapid decline of estimated glomerular filtration rate and its effect on mortality risk of patients with hepatocellular carcinoma. *Hepatitis Monthly*, 23(1), e133853. <https://doi.org/10.5812/hepatmon-133853>
- Goyal, A., Daneshpajouhnejad, P., Hashmi, M. F., & Bashir, K. (2025). Acute Kidney Injury. In *StatPearls*. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK441896/>
- Gupta, K., Bhurwal, A., Law, C., Ventre, S., Minacapelli, C.D., Kabaria, S., Li, Y., Tait, C., Catalano, C., Rustgi, V.K. (2021). Acute kidney injury and hepatorenal syndrome in cirrhosis. *World J Gastroenterol*. Jul, 27(26):3984-4003. doi: 10.3748/wjg.v27.i26.3984
- Hasan, I., Rashid, T., Chirila, R. M., Ghali, P., & Wadei, H. M. (2021). Hepatorenal syndrome: pathophysiology and evidence-based management update. *Rom J Intern Med*, 59(3), 227–261. <https://doi.org/10.2478/rjim-2021-0006>
- Hassanipour, S., Vali, M., Gaffari-fam, S., Nikbakht, H.-A., Abdzadeh, E., Joukar, F., Pourshams, A., Shafagni, A., Malakoutikhah, M., Arab-Zozani, M., Salehiniya, H., & Mansour-Ghanaei, F. (2020). The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis. *EXCLI J*, 19, 108–130. <https://doi.org/10.17179/excli2019-1842>
- He, C., Zhang, X., Li, C., Peng, W., Wen, T.F., Yan, L.N., Yang, J., Lu, W. (2017). Changes of alpha-fetoprotein levels could predict recurrent hepatocellular carcinoma survival after trans-arterial chemoembolization. *Oncotarget*, 18;8(49):85599-85611. doi: 10.18632/oncotarget.20343
- Ho, S.-Y., Hsu, C.-Y., Liu, P.-H., Ko, C.-C., Huang, Y.-H., Su, C.-W., Lee, R.-C., Hou, M.-C., & Huo, T. (2020). Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade. *Cancers (Basel)*, 12(5), 1130. <https://doi.org/10.3390/cancers12051130>
- Hwang, J.-C., Weng, S.-F., & Weng, R.-H. (2012). High incidence of hepatocellular carcinoma in ESRD patients: caused by high hepatitis rate or “uremia”? a population-based study. *Jpn J Clin Oncol*, 42(9), 780–786. <https://doi.org/10.1093/jjco/hys100>
- Jasirwan, C. O. M., Hasan, I., Sulaiman, A. S., Lemana, C. R. A., Kurniawan, J., Kalista, K. F., Nababan, S. H., & Gani, R. A. (2020). Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia. *Curr Probl Cancer*, 44(1), 100480. <https://doi.org/10.1016/j.currproblcancer.2019.05.003>

- Jung, C.-Y., & Chang, J. W. (2023). Hepatorenal syndrome: Current concepts and future perspectives. *Clinical and Molecular Hepatology*, 29, 891–908. <https://doi.org/10.3350/cmh.2023.0024>
- Kim, E., & Viatour, P. (2020). Hepatocellular carcinoma: old friends and new tricks. *Exp Mol Med*, 52(12), 1898–1907. <https://doi.org/10.1038/s12276-020-00527-1>
- Kolu, M., Dere, O., Sonmez, S. (2021). The effect of transarterial chemoembolization therapy on survival in patients with non-resectable hepatocellular carcinoma: Single-center study results. *Hepatol Forum*, 15;2(3):102-106. doi: 10.14744/hf.2021.2021.0029.
- Kudaravalli, S., Kam, L. Y., Huang, D. Q., Cheung, R., & Nguyen, M. H. (2023). Utilization of antiviral therapy for patients with hepatitis B–related hepatocellular carcinoma: A nationwide real-world US study. *Clinical Gastroenterology and Hepatology*, Advance online publication. <https://doi.org/10.1016/j.cgh.2023.04.020>
- Lee, C.-H., Hsieh, S.-Y., Chang, C.-C., Wang, I.-K., Huang, W.-H., Weng, C.-H., Hsu, C.-W., & Yen, T.-H. (2017). Hepatocellular carcinoma in hemodialysis patients. *Oncotarget*, 8(42), 73154–73161. <https://doi.org/10.18632/oncotarget.17127>
- Lee, C.-H., Hsieh, S.-Y., Lin, J.-L., Liu, M.-S., & Yen, T.-H. (2013). Hepatocellular carcinoma in patients with chronic kidney disease. *World J Gastroenterol*, 19(16), 2466–2472. <https://doi.org/10.3748/wjg.v19.i16.2466>
- Lestari, D. A., Syaiful, R. A., & Jeo, W. S. (2021). *Kesintasan karsinoma sel hati pascareseksi pada karakteristik pasien di RS Dr. Cipto Mangunkusumo dan faktor-faktor yang memengaruhi = Post resection survival rate of hepatocellular carcinoma patients in DR Cipto Mangunkusumo National General Hospital and [Universitas Indonesia]*. <https://lib.ui.ac.id/detail?id=20523330&lokasi=lokal>
- Liu, X.-Y., Zhao, Z.-Q., Cheng, Y.-X., Tao, W., Yuan, C., Zhang, B., & Wang, C.-Y. (2022). Does Chronic Kidney Disease Really Affect the Complications and Prognosis After Liver Resection for Hepatocellular Carcinoma? A Meta-Analysis. *Front Surg*, 9, 870946. <https://doi.org/10.3389/fsurg.2022.870946>
- Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021). Hepatocellular Carcinoma. *Nature Reviews Disease Primers*, 7(1), 1–28. <https://doi.org/10.1038/s41572-020-00240-3>
- Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., Oliveira, A. C. de, Santoro, A., Raoul, J.-L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T. F., Galle, P. R., Seitz, J.-F., Borbath, I., Häussinger, D., ... Bruix, J. (2008). Sorafenib in advanced hepatocellular

- carcinoma. *New England Journal of Medicine*, 359(4), 378–390. <https://doi.org/10.1056/NEJMoa0708857>
- Lockart, I., Hajarizadeh, B., Buckley, N., Davison, S., Emilia, P., Levy, M. T., George, J., Dore, G. J., & Danta, M. (2021). All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy. *J Gastroenterol Hepatol*, 36(12), 3515–3523. <https://doi.org/10.1111/jgh.15687>
- Loho, I. M., Hasan, I., Lesmana, C. R. A., Dewiasty, E., & Gani, R. A. (2016). Hepatocellular Carcinoma in a Tertiary Referral Hospital in Indonesia: Lack of Improvement of One-Year Survival Rates between 1998-1999 and 2013-2014. *Asian Pac J Cancer Prev*, 17(4), 2165–2170. <https://doi.org/10.7314/apjcp.2016.17.4.2165>
- Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018). Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases Journal Hepatology Volume 68 Issue 2 Pages 723-750 DOI (Jika ada, bisa ditambahkan untuk mempermudah verifikasi. *Hepatology*, 68(2), 723–750. <https://doi.org/10.1002/hep.29913>
- Mou, Z., Guan, T., & Chen, L. (2022). Acute Kidney Injury in Adult Patients With Hepatocellular Carcinoma After TACE or Hepatectomy Treatment. *Front Oncol*, 12, 627895. <https://doi.org/10.3389/fonc.2022.627895>
- Mulyana. (2001). *Analisis kesintasan pasien hepatoma di RSUPN-CM Jakarta*. Fakultas Kedokteran Universitas Indonesia.
- Novian, R., Ratnasari, N., & Triwikatmani, C. (2022). *Analisis Kesintasan Pasien Karsinoma Sel Hati Yang Menjalani Transarterial Chemoembolization Berdasarkan Kriteria Up To Seven* [Universitas Gadjah Mada]. <https://etd.rerepository.ugm.ac.id>
- Ostermann, M., Lumlertgul, N., Jeong, R., See, E., Joannidis, M., & James, M. (2025). Acute kidney injury. *The Lancet*, 405(10474), 241–256. [https://doi.org/10.1016/S0140-6736\(24\)02385-7](https://doi.org/10.1016/S0140-6736(24)02385-7)
- Okushin, K., Yamana, H., Tateishi, R., Sato, M., Tsutsumi, T., Matsui, H., Fushimi, K., Yasunaga, H., Koike, K., & Fujishiro, M. (2023). Treatment and outcome of hepatorenal syndrome in Japan: a retrospective cohort study using a national inpatient database. *BMC Gastroenterol*, 23(1), 218. <https://doi.org/10.1186/s12876-023-02858-5>
- Ozturk, N. B., Dinc, E. J., Swami, A., & Gurakar, A. (2024). Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis. *Journal of Clinical Medicine*, 13(1), 199. <https://doi.org/10.3390/jcm13010199>

- Peng ,X., Cai, Y., Huang, H., Fu, H., Wu, W., Hong, L. (2025). A Predictive Model for Acute Kidney Injury Based on Leukocyte-Related Indicators in Hepatocellular Carcinoma Patients Admitted to the Intensive Care Unit. *Mediators Inflamm*, 16;2025:7110012. doi: 10.1155/mi/7110012.
- Pereira, M., Rodrigues, N., Godinho, I., Gameiro, J., Neves, M., Gouveia, J., Silva, Z. C., & Lopes, J. A. (2017). Acute kidney injury in patients with severe sepsis or septic shock: a comparison between the “Risk, Injury, Failure, Loss of kidney function, End-stage kidney disease” (RIFLE), Acute Kidney Injury Network (AKIN) and Kidney Disease: Improving Global Outcom. *Clin Kidney J*, 10(3), 332–340. <https://doi.org/10.1093/ckj/sfw107>
- Pose, E., Piano, S., Juanola, A., & Ginès, P. (2024). Hepatorenal Syndrome in Cirrhosis. *Hepatorenal Syndrome in Cirrhosis*, 166(4), 588-604.e1. <https://doi.org/10.1053/j.gastro.2023.11.306>
- Prestigiacomo, V., Weston, A., Messner, S., Lampart, F., & Suter-Dick, L. (2017). Pro-fibrotic compounds induce stellate cell activation, ECM-remodelling and Nrf2 activation in a human 3D-multicellular model of liver fibrosis. *PLoS ONE*, 12(6), e0179995. <https://doi.org/10.1371/journal.pone.0179995>
- Ranasinghe, I. R., Sharma, B., & Bashir, K. (2025). Hepatorenal Syndrome. In *StatPearls*. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK430856/>
- Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Gracia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., Sangro, B., Singal, A. G., Vogel, A., Fuster, J., Ayuso, C., & Bruix, J. (2022). BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. *Journal of Hepatology*, 76(3), 681–693. <https://doi.org/10.1016/j.jhep.2021.11.018>
- Renne, S. L., Sarcognato, S., Sacchi, D., Guido, M., Roncalli, M., Terracciano, L., & Tommaso, L. Di. (2021). Hepatocellular carcinoma: a clinical and pathological overview. *Pathologica*, 113(3), 203. <https://doi.org/10.32074/1591-951X-295>
- Ripoll, C., Platzer, S., Franken, P. et al.(2023). Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis—a randomized controlled trial. *Trials* 24, 258. <https://doi.org/10.1186/s13063-023-07261-9>
- Shah, P. A., Patil, R., & Harrison, S. A. (2023). NAFLD-related hepatocellular carcinoma: The growing challenge. *Hepatology*, 77(1), 323–338. <https://doi.org/10.1002/hep.32542>
- Simonetto, D. A., Gines, P., & Kamath, P. S. (2020). Hepatorenal syndrome: pathophysiology, diagnosis, and management. *BMJ*, 370, m2687. <https://doi.org/10.1136/bmj.m2687>

- Sohn, W., Ham, C. B., Kim, N. H., Kim, H. J., Cho, Y. K., Jeon, W. K., & Kim, B. I. (2020). Effect of acute kidney injury on the patients with hepatocellular carcinoma undergoing transarterial chemoembolization. *PLoS ONE*, *15*(12), e0243780. <https://doi.org/10.1371/journal.pone.0243780>
- Su, T.S., Yang, H.M., Zhou, Y. et al. (2019). Albumin - bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy. *Radiat Oncol* *14*, *50*. <https://doi.org/10.1186/s13014-019-1251-y>
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, *71*(3), 209–249. <https://doi.org/10.3322/caac.21660>
- Tsai, H.-W., Lee, Y.-P., Yen, C.-J., Kuang-Hsiung, C., Huang, C.-J., & Huang, W. (2022). The Serum Hepatitis B Virus Large Surface Protein as High-Risk Recurrence Biomarker for Hepatoma after Curative Surgery. *Int J Mol Sci*, *23*(10), 5376. <https://doi.org/10.3390/ijms23105376>
- Villanueva, A. (2019). Hepatocellular Carcinoma. *New England Journal of Medicine*, *380*(15), 1450–1462. <https://doi.org/10.1056/NEJMra1713263>
- Wiedermann, C.J., Wiedermann, W., Joannidis, M. (2017). Causal relationship between hypoalbuminemia and acute kidney injury. *World J Nephrol*, *6*;6(4):176-187. doi: 10.5527/wjn.v6.i4.176
- Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019). A global view of hepatocellular carcinoma: trends, risk, prevention and management. *Nat Rev Gastroenterol Hepatol*, *16*(10), 589–604. <https://doi.org/10.1038/s41575-019-0186-y>
- Yeh, H., Chiang, C.-C., & Yen, T.-H. (2021). Hepatocellular Carcinoma in Patients with Renal Dysfunction: Pathophysiology, prognosis, and treatment challenges. *World J Gastroenterol*, *27*(26), 4104–4142. <https://doi.org/10.3748/wjg.v27.i26.4104>
- Zhang, C.-H., Chen, Y., Zhang, S., Fan, J., & Gao, Q. (2022). Changing epidemiology of hepatocellular carcinoma in Asia. *Liver Int*, *42*(9), 2029–2041. <https://doi.org/10.1111/liv.15251>
- Zhou, W.-C., Zhang, Q.-B., & Qiao, L. (2014). Pathogenesis of liver cirrhosis. *World J Gastroenterol*, *20*(23), 7312–7321. <https://doi.org/10.3748/wjg.v20.i23.7312>